ReviewFrontiers in genetics2026
Long noncoding RNAs in tumor stemness: emerging mechanisms and therapeutic opportunities.
Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) constitute a subpopulation of malignant cells with self-renewal and differentiation capabilities that drive tumorigenicity, metabolic adaptability, immune evasion, and therapeutic resistance, key factors contributing to metastasis and poor clinical outcomes. While genetic drivers of tumorigenesis are well-characterized, the epigenetic machinery sustaining the CSC state remains complex. Long noncoding RNAs (lncRNAs) represent a vast yet poorly understood class of regulatory molecules that influence gene expression at epigenetic, transcriptional, and post-transcriptional levels. Emerging evidence indicates that lncRNAs play a crucial role in shaping tumor cell plasticity and stemness-associated phenotypes. In this mini-review, we summarize current findings on how lncRNAs regulate CSC biology. We categorize their mechanisms of action, ranging from chromatin remodeling to the modulation of mRNA and protein stability. Furthermore, we discuss how the advent of high-resolution omics, including bulk tissue, single-cell, and spatial transcriptomics studies, is revolutionizing the identification CSC-associated lncRNAs and contributing to the development of clinically relevant biomarkers. Finally, we explore advanced methodologies for manipulating lncRNA expression, assessing the challenges and opportunities of lncRNA-directed therapeutics as a novel strategy to dismantle tumor plasticity and overcome drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.